News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
ARTHEx Biotech Announces FDA Rare Pediatric Designation (RPD) of ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)
Thursday, November 07, 2024ARTHEx Biotech SL a clinicalstage biotechnology company focused on developing innovative medicines through the modulation of gene expression today announced that the US Food and Drug Administration FDA has granted Rare Pediatric Designation RPD to AT...
BioIVT LLC and KRISHGEN BioSystems Announce Exclusive Commercial Agreement to Enhance Clinical Research in South Asia
Thursday, November 07, 2024BioIVT a global research partner and biospecimen solutions provider for drug and diagnostic development today announced an exclusive agreement with KRISHGEN BioSystems a leading provider of life science research tools and services for over two decade...
Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment
Wednesday, November 06, 2024Insignis Therapeutics a leader in innovative allergy and anaphylaxis treatments announced today that it has received positive feedback from the US Food and Drug Administration FDA with regard to its clinical development program for IN a needle free e...
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
Wednesday, November 06, 2024Regeneron Pharmaceuticals Inc and Sanofi today announced that the European Commission EC has approved Dupixent dupilumab to treat eosinophilic esophagitis EoE in children as young as year of age Specifically the approval covers children aged to ye...
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
Tuesday, November 05, 2024Ascendis Pharma AS announced that it has granted Novo Nordisk AS an exclusive worldwide license to the TransCon technology platform to develop manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases including obesity and...
Parse Biosciences Launches Evercode Low Input Fixation for Cells and Nuclei
Tuesday, November 05, 2024Parse Biosciences a leading provider of accessible and scalable single cell sequencing solutions today announced the launch and availability of Evercode Low Input Fixation kits for both cells and nuclei The new kits empower researchers who have a sma...
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics
Monday, November 04, 2024QIAGEN announced that the US Food and Drug Administration FDA has cleared the QIAstatDx MeningitisEncephalitis Panel for clinical use This marks the fourth QIAstatDx syndromic test to receive US regulatory clearance in
PURE Bioscience Announces Distribution Agreement with Quip Laboratories
Saturday, November 02, 2024PURE Bioscience Inc creator of the patented nontoxic silver dihydrogen citrate SDC antimicrobial and Quip Laboratories Inc have entered into a multiyear distribution agreement for the purchase and selling of SDC products under special terms and condi...
Hyperfine Announces Alzheimer’s Research with Promising Swoop® System Data and Advanced Image Quality
Friday, November 01, 2024Hyperfine Inc the groundbreaking health technology company that has redefined brain imaging with the first FDAcleared portable magnetic resonance MR brain imaging systemthe Swoop systemtoday announced the presentation of additional research data and...
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)
Friday, November 01, 2024Spur Therapeutics today announced the publication of preclinical proofofconcept data for SBT its potential firstinclass gene therapy program for the treatment of adrenomyeloneuropathy AMN in Molecular Therapy Methods Clinical Development AMN is a ra...
